HOME >> BIOLOGY >> NEWS
FDA approves AVELOX (moxifloxacin HCl) for treatment of complicated intra-abdominal infections

as effective as the widely used I.V. therapy piperacillin-tazobactam four times daily followed by oral amoxicillin-clavulanate twice daily. AVELOX was effective at eradicating key pathogens, including E. coli and the anaerobe B. fragilis, which are the most commonly encountered bacteria in cIAI.

"This FDA approval signals yet another important milestone for AVELOX, following the approval of AVELOX for treatment of complicated skin and skin structure infections in June," said Robert J. Spiegel, M.D., chief medical officer and senior vice president of medical affairs, Schering-Plough Research Institute. "By adding two new indications this year, AVELOX has successfully expanded its utility as a broad-spectrum antibiotic. This will help toward AVELOX becoming a fluoroquinolone of choice for its approved indications."

Patients taking AVELOX for cIAI treatment benefit from the convenience of once-daily therapy and not requiring dosage adjustments when switching from I.V. to oral therapy. Dosage adjustments also are not required for AVELOX patients suffering from renal impairment.

In October 2004, Schering-Plough acquired exclusive U.S. rights to market, sell and distribute AVELOX from Bayer Pharmaceuticals Corporation. As holder of the New Drug Application (NDA) and patents for AVELOX, Bayer completed the research and FDA submission related to this new indication.

The FDA approval to treat cIAI is the sixth indication for AVELOX, which is already approved in the United States to treat acute bacterial sinusitis (ABS); acute bacterial exacerbation of chronic bronchitis (ABECB); community acquired pneumonia (CAP) including CAP caused by multi-drug resistant Streptococcus pneumoniae (MRSP) and penicillin-resistant Streptococcus pneumoniae (PRSP); uncomplicated skin and skin structure infections (uSSSI); and complicated skin and skin structure infections (cSSSI).


'"/>


30-Nov-2005


Page: 1 2

Related biology news :

1. FDA approves new epilepsy indication for Lamictal
2. US govt approves multi-million $ wild bird avian flu surveillance network
3. FDA approves extended dosing of Aranesp
4. FDA approves first medical device using Rutgers biomaterial
5. DFG approves additional six research training groups
6. FDA approves ABRAXANE(TM) for metastatic breast cancer
7. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections
8. New system of wastewater treatment could reduce the size of treatment plants by half
9. UCF research links proteins, stem cells and potential Alzheimers treatment
10. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
11. System to analyze beating heart stem cells could lead to heart attack treatments

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2018)... ... December 04, 2018 , ... Lifecycle ... launch of their 100-liter (26 gallon) SAFEthread Drum. The 100-liter SAFEthread Drum ... which brought a much-needed modern redesign to the plastic drums being used globally. ...
(Date:12/5/2018)... SAN DIEGO (PRWEB) , ... December 04, 2018 ... ... to leverage Fastec’s extensive expertise and existing IP in the development of innovative ... technology has been integrated into diverse systems from microfluidics to industrial machinery and ...
(Date:11/29/2018)... (PRWEB) , ... November 29, 2018 , ... ... in Semba Biosciences with the intention of acquiring full ownership. The transaction was ... Agreement was executed on November 14, 2018. “We are extremely pleased to team ...
Breaking Biology News(10 mins):
(Date:11/26/2018)... ... November 26, 2018 , ... USARAD Holdings Inc., ... Omphalos Venture Partners (Virtual Radiologic founders) among other healthcare investors exhibits at the ... McCormick Place in Chicago. The company is proud to announce a 10 year ...
(Date:11/20/2018)... ... November 20, 2018 , ... Each year Forbes receives thousands of nominations for ... outstanding performance by individuals under 30 years of age. The Forbes 30 Under 30 ... and Entertainment to Venture Capital and Science. , In 2017, Visikol CEO Dr. ...
(Date:11/13/2018)... ... 13, 2018 , ... Renowned Honolulu veterinarian, Dr. Patrick Leadbeater, has begun offering ... Dr. Leadbeater, of Kahala Pet Hospital on Oahu, is a skilled surgeon ... to the island of Kauai on an almost weekly basis to perform surgery at ...
(Date:11/13/2018)... ... 2018 , ... Aditya Humad, Managing Partner of KICVentures ... it is still trending upward with growing valuations based on a largely under-served ... pricing pressure and increased competition as reasons often cited by institutional investors to ...
Breaking Biology Technology:
Cached News: